Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin Journal Article
| Authors: | Grant, S. C.; Kris, M. G.; Houghton, A. N.; Chapman, P. B. |
| Article Title: | Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin |
| Abstract: | Despite active therapies for small cell lung cancer (SCLC), most patients relapse and die of the disease. The present study evaluates immunization using the anti-idiotypic antibody BEC2, which mimics the ganglioside GD3 expressed on the surface of most SCLC tumors, combined with Bacillus Calmette-Guerin (BCG) as an immune adjuvant. We hypothesized that active immunization could alter the natural history of the disease. Fifteen patients who had completed standard therapy for SCLC received a series of five intradermal immunizations consisting of 2.5 mg of BEC2 plus BCG over a 10-week period. Blood was collected for serological analysis, and outcome was monitored. All patients developed anti-BEC2 antibodies, despite having received chemotherapy with or without thoracic radiation. We detected anti- GD3 antibodies in five patients, including those with the longest relapse- free survival. The median relapse-free survival for patients with extensive stage disease is 11 months and has not been reached for patients with limited stage disease (>47 months), with only one of seven patients having relapsed after a median follow-up of 47 months. Immunization of patients with SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies and is safe. The survival and relapse-free survival in this group of patients are substantially better than those observed in a prior group of similar patients. A Phase III trial is being conducted to evaluate BEC2 plus BCG as adjuvant therapy after chemotherapy and irradiation. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; disease-free survival; middle aged; survival rate; unclassified drug; drug tolerability; cancer recurrence; drug safety; side effect; cancer adjuvant therapy; bcg vaccine; lung neoplasms; lung small cell cancer; immunoglobulin g; antibody response; adjuvants, immunologic; immunosuppressive treatment; humoral immunity; ganglioside gd3; immunoglobulin m; carcinoma, small cell; immunization; intradermal drug administration; gangliosides; antibodies, anti-idiotypic; immunotherapy, active; antiidiotypic antibody; humans; human; male; female; priority journal; article; bec 2; theracys |
| Journal Title: | Clinical Cancer Research |
| Volume: | 5 |
| Issue: | 6 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 1999-06-01 |
| Start Page: | 1319 |
| End Page: | 1323 |
| Language: | English |
| PUBMED: | 10389914 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 16 August 2016 -- Source: Scopus |
Citation Impact
Related MSK Work